Aging Male 23 (5), 11151124
First identified as a potential cognitive enhancer in 1996 by Terranova and colleagues at the French pharmaceutical development firm, Sanofi, Rimonabant was found to be of interest due to its ability to reverse the inhibition of hippocampal synaptic plasticity caused by the CBR1 agonist, WIN 55,212-2
For broader vendor evaluation strategies, the vendor comparison guide covers the key factors to assess
In some cases, acute liver failure may occur, which can be life-threatening and require immediate medical intervention
BPC-157 is considered a research peptide, or research chemical, which means its not actually legal to sell BPC-157 for human use in the U.S